The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study
Juurlink, D. N., Mamdani, M. M., Lee, D. S., Kopp, A., Austin, P. C., Laupacis, A., & Redelmeier, D. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040135 · Cited by 1,761
Calhoun, D. A., White, W. B., Krum, H., Guo, W., Bermann, G., Trapani, A., Lefkowitz, M. P., & Ménard, J. (2011) · Circulation · doi:10.1161/circulationaha.111.029892 · Cited by 227 · cited 1×
“Noteworthy, review of available scientific evidence discloses that 11 randomized clinical trials assessing eplerenone in >3,500 hypertensives have been reported so far [16-26].”
Background
Cited by
New progress in drugs treatment of diabetic kidney disease
Wang, J., Xiang, H., Lu, Y., Wu, T., & Ji, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111918 · Cited by 74
A meta-analysis of add-on use of spironolactone in patients with resistant hypertension
Zhao, D., Liu, H., Dong, P., & Zhao, J. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.12.158 · Cited by 60
Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis
Bommareddy, K., Hamade, H., Lopez-Olivo, M. A., Wehner, M., Tosh, T., & Barbieri, J. S. (2022) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.5866 · Cited by 49
“17-19 This scale uses a 9-star system evaluating 3 domains: (1) seKey Points”
MethodFernet, M., Beckerman, B., Abreu, P., Lins, K., Vincent, J., & Burgess, E. (2018) · Vascular Health and Risk Management · doi:10.2147/vhrm.s170141 · Cited by 7
Metadata
- Authors
- Lainscak, M., Pelliccia, F., Rosano, G., Vitale, C., Schiariti, M., Greco, C., Speziale, G., & Gaudio, C.
- Venue
- International Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 200
- Pages
- 25-29
- ISSN
- 0167-5273 (ISSN-L)
- OpenAlex
- W1817639972
- Cited by
- 187
- References
- 3
- FWCI
- 8.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. https://app.cochat.ai/papers/10.1016/j.ijcard.2015.05.127
- The paper
- Lainscak, M., Pelliccia, F., Rosano, G., Vitale, C., Schiariti, M., Greco, C., Speziale, G., & Gaudio, C. (2015). Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. International Journal of Cardiology. https://doi.org/10.1016/j.ijcard.2015.05.127
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.